Literature DB >> 10948696

Indirect-response modeling of desmopressin at different levels of hydration.

T Callréus1, J Odeberg, S Lundin, P Höglund.   

Abstract

The objective of the present study was to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of desmopressin in healthy male subjects at different levels of overhydration. Also, we examined if an indirect-response model could be related to renal physiology and the pharmacological action of desmopressin. Eight healthy male subjects participated in this open, randomized crossover study with three periods. Each subject was orally water loaded (0 to 20 ml.kg-1 body weight) on 3 study days in order to achieve three different levels of hydration. After the initial water load, urine was voided every 15 min and the volumes were measured. To ensure continuous overhydration the subjects replaced their fluid loss with drinking-water. When a steady-state diuresis was achieved after approximately 2 hr, 0.396 microgram of desmopressin was administered intravenously as a bolus injection. Blood was sampled and urine was collected at intervals throughout the study day (10 hr). An indirect-response model, where desmopressin was assumed to inhibit the elimination of response, was fit to the urine osmolarity data. There were no statistically significant effects of different levels of hydration, as expressed by urine flow rate at baseline, on the estimates of the PK and PD model parameters. The calculated terminal half-lives of elimination (t1/2 beta) ranged between 2.76 and 8.37 hr with an overall mean of 4.36 hr. The overall means of plasma clearance and the volumes of distribution of the central compartment (Vc) and at steady state (Vss) were estimated to be 1.34 (SD 0.35) ml.min-1.kg-1, 151 (SD28) ml.kg-1, and 386 (SD 63) ml.kg-1, respectively. High urine flow rate, indicating overhydration, produced a diluted urine and thus a low osmolarity at baseline (R0). The effect of the urine flow rate on the urine osmolarity at baseline was highly significant (p < 0.0001). The mean values for IC50 and the sigmodicity factor (gamma) were 3.7 (SD 1.2) pg ml-1 and 13.0 (SD 3.5), respectively. In most cases when there was a high urine flow rate at baseline, the model and the estimated PD parameters could be related to the pharmacological action of desmopressin and renal physiology. Thus, the indirect-response model used in this study offers a mechanistic approach of modeling the effect of desmopressin in overhydrated subjects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10948696     DOI: 10.1023/a:1023238514015

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  16 in total

1.  DDAVP in the treatment of central diabetes insipidus.

Authors:  A G Robinson
Journal:  N Engl J Med       Date:  1976-03-04       Impact factor: 91.245

2.  Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers.

Authors:  T Callréus; P Höglund
Journal:  Pharmacol Toxicol       Date:  1998-12

3.  The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide.

Authors:  M Wakelkamp; G Alván; G Paintaud
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 4.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.

Authors:  A Sharma; W J Jusko
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

5.  Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects.

Authors:  S Rittig; A R Jensen; K T Jensen; E B Pedersen
Journal:  Clin Endocrinol (Oxf)       Date:  1998-02       Impact factor: 3.478

6.  Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans.

Authors:  H Vilhardt; S Lundin
Journal:  Gen Pharmacol       Date:  1986

7.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

8.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects.

Authors:  W J Jusko; H C Ko
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

Review 9.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

10.  Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-D-arginine vasopressin. 1. Studies in adults and children.

Authors:  T D Williams; D B Dunger; C C Lyon; R J Lewis; F Taylor; S L Lightman
Journal:  J Clin Endocrinol Metab       Date:  1986-07       Impact factor: 5.958

View more
  5 in total

1.  Effects of Food and Pharmaceutical Formulation on Desmopressin Pharmacokinetics in Children.

Authors:  Robin Michelet; Lien Dossche; Pauline De Bruyne; Pieter Colin; Koen Boussery; Johan Vande Walle; Jan Van Bocxlaer; An Vermeulen
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

2.  Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.

Authors:  Robin Michelet; Lien Dossche; Charlotte Van Herzeele; Jan Van Bocxlaer; An Vermeulen; Johan Vande Walle
Journal:  Eur J Clin Pharmacol       Date:  2017-12-03       Impact factor: 2.953

3.  An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?

Authors:  Robin Michelet; Lien Dossche; Charlotte Van Herzeele; Pauline De Bruyne; Elke Gasthuys; Jan Van Bocxlaer; Johan Vande Walle; An Vermeulen
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447

4.  Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients.

Authors:  Henrik Agersø; Lotte Seiding Larsen; Anders Riis; Ulf Lövgren; Mats O Karlsson; Thomas Senderovitz
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

5.  A novel clinical nomogram for the evaluation of disorders of plasma osmolality.

Authors:  Philip J G M Voets; Nils P J Vogtländer; Karin A H Kaasjager
Journal:  Clin Kidney J       Date:  2021-02-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.